Cor MDx
Next-generation IoT ECG wearable with wireless connectivity for AI-driven cardiac care
Device · Cloud SaaSCompany source
Company profile
About Peerbridge Health
Peerbridge Health is a medical technology company transforming cardiac care through its FDA-cleared Cor ambulatory ECG system. The company's wearable platform captures high-fidelity physiological signals using a patented multi-lead, 2-channel wireless patch based on Einthoven's Triangle design, enabling detection of 31 cardiac rhythms with clear P-wave definition and precise QRS morphology. Peerbridge's technology is designed to integrate seamlessly into existing clinical workflows, keeping care and billing with physicians while delivering consistent, decision-ready reports without administrative burden. The platform serves primary care, cardiology practices, and medical research professionals, enabling continuous monitoring outside clinical settings and on-demand diagnostics with less than 10 minutes of wear time. The company is advancing an innovation roadmap focused on expanding clinical insights across electrical, structural, and functional cardiac mechanisms through a unified wearable solution. Peerbridge aims to address the 6 million Americans living with heart failure and 45 million with asymptomatic heart failure by enabling earlier detection and hospital-grade diagnostics in home and ambulatory settings. The company has demonstrated a 95.7% success rate in early detection of heart failure trials and is conducting the COR-INSIGHT Trial to validate AI-enabled cardiac diagnostics and monitoring capabilities.
Company description Peerbridge Health official website
Primary marketCardiology & Cardiovascular Health
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Peerbridge Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Cardiac arrhythmias
- Cardiac remodeling
- Conduction defects
- Electrical dyssynchrony
- Heart failure
- Silent ischemia
- Systolic and diastolic dysfunction
Who it serves
- Cardiology practices
- Health systems
- Medical research professionals
- Primary care clinics
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Selected for MedTech Innovator 2025 Cohort. Announced funding round close and FDA 510(k) submission of next-generation Cor MDx device. Unveiled Cor MDx IoT ECG wearable at HIMSS Global Health Conference. Launched COR-INSIGHT Trial for AI-enabled cardiac diagnostics validation.
Partnerships
Recorded partners
- AT&T (wireless connectivity)
- Northwell Health
- Saint Joseph Hospital Orange County
- Texas Cardiac Arrhythmia Center
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Peerbridge Cor
FDA-cleared ambulatory ECG wearable with AI-enabled cardiac monitoring and diagnostics
Device · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care PathwaysNCT07775976 · Sponsor · ENROLLING BY INVITATION
Regulatory
Regulatory records
Peerbridge Cor(TM) SystemK171936 · 510k · Sep 27, 2017
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
95.7% success rate
Early detection of heart failure in clinical trial
Earlier detection and intervention
Enabling timely intervention before conditions escalate
COR-INSIGHT Trial
Early detection of heart failure using AI-enabled cardiac diagnostics and monitoring
95.7% success rate in early detection of heart failure
Northwell Health
Improved monitoring and treatment of heart failure and cardiac patients throughout continuum of care
Significant clinical value across clinic, hospital, and home settings
Saint Joseph Hospital, Orange County
Early intervention before emergency visits and expanding care to previously unreached patients
Inexpensive expansion of care to patients not currently being reached
Texas Cardiac Arrhythmia Center
Transformative multipurpose diagnostic tool facilitating early interventions for cardiovascular patients
Enhancing quality of life for cardiovascular patients through early intervention
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Chris Darland
Chief Executive Officer
Angelo Acquista
Chief Medical Officer
Sandeep Gulati
Chief Technology Officer
Leah Rubin
Head of Commercial Strategy & Growth
Vitale Meertens
Head of Clinical Product & Innovation
Dan Reuvers
Director
Pat Horan
Director
Mark Bakken
Director
06 · Company updates
Updates from Peerbridge Health
Recent articles published on Peerbridge Health's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Cardiology & Cardiovascular Health
Companies applying AI to cardiovascular disease detection, ECG/EKG analysis, heart failure management, cardiac imaging, arrhythmia detection, or cardiovascular risk assessment. Includes AI-powered cardiac diagnostics, non-invasive hemodynamic monitoring, and tools for early detection and personalized management of heart conditions.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.